Page 156 - CW E-Magazine (24-12-2024)

News from Abroad

CO-LOCATION BENEFITS
PCC Group plans chlor-alkali facility at Chemours

titanium dioxide site in US

German chemicals, silicon and logis- Mr. Peter Wenzel, CEO, PCC SE,
tics operator PCC Group (PCC) is plann- remarked, “We are dedicated to using
ing to build and operate a chlor-alka- our decades-long experience to safely
li facility on the grounds of Chemours’ and responsibly extend our chemical
titanium dioxide (TiO ) plant in DeLisle, business at this facility. We look forward
2
Mississippi (USA). to a successful collaboration with such
a major, globally renowned player as
US-based Chemours informed it Chemours, setting a benchmark in the
has also entered into a chlorine supply industry while evaluating further oppor-
agreement with PCC, which is subject to tunities in the region.”
certain customary conditions precedent. Ms. Denise Dignam, President and
The new facility will utilise state-of-the- CEO of Chemours, pointed out that the PCC SE is the parent and invest-
art technology to maximise energy effi - onsite chlorine facility will help pro- ment holding company of PCC Group.
ciency and provide up to a nameplate vide supply reliability for its TiO faci- The largest chemical producers of the
2
capacity of 340-ktpa once the plant is lity. “This new partnership, requiring PCC Group are PCC Rokita SA, a major
operational. The co-product, caustic soda, no up-front fi nancial commitment from chlorine manufacturer and Eastern
will be sold by PCC to strategic partners Chemours, will enable us to lower our Europe’s leading producer of polyols, and
and on the open market. Construction is manufacturing costs and better serve our surfactant maker, PCC Exol SA. PCC
expected to begin in early 2026 with the customers as their trusted TiO partner BakkiSilicon hf operates silicon produc-
2
plant being operational in 2028. of choice,” she added. tion facilities in Iceland.
NOVE L CHEMICAL ENTITIES
LVMH Recherche and Integrated Biosciences in research

alliance to target aging at molecular level

French beauty giant, LVMH, has
announced that its Beauty R&D Divi-
sion, LVMH Recherche, and US-based
Integrated Biosciences have entered a
research partnership to discover novel
chemical entities that target aging at the
molecular level.
identifying the most promising fi rst- Integrated Biosciences is known for
This multi-year partnership will in-class chemical compounds that pioneering the AI-driven discovery of
leverage Integrated Biosciences’ syn- potently modulate age-related biological novel senolytic compounds – anti-
thetic biology and artifi cial intelligence phenotypes. aging chemical entities that selectively
(AI)-based platform for science-backed clear pathological senescent “zombie”
skin youth and beauty products. The company has consistently cells.
reported on its drug discovery engine in
Thanks to a combination of its pro- leading scientifi c journals. Founded by Commenting on the partnership,
prietary AI and optogenetics platforms, scientists at MIT, Harvard University, Mr. Bruno Bavouzet, President of
Integrated Biosciences can train deep and the University of California Santa LVMH Recherche, said, “This repre-
learning models to virtually screen Barbara and having recently announced sents a unique opportunity to evaluate
hundreds of thousands of molecules, a fundraise led by Sutter Hill Ventures, thousands of potential bioactives

156 Chemical Weekly December 24, 2024

Contents Index to Advertisers Index to Products Advertised